Matthew K. Fust
Director · Crinetics Pharmaceuticals, Inc.
IndividualSelling only12 10b5-1 trades
- 2024
- Sep 1, 2026
- 7
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Matthew K. Fust files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Jeff E. Knight - $3.79M in CRNX purchases and sales in the last 12 months
- Richard Scott Struthers - $822K in CRNX purchases and sales in the last 12 months
- Dana Pizzuti - $438K in CRNX purchases and sales in the last 12 months
- Stephen F. Betz - $397K in CRNX purchases and sales in the last 12 months
- Stephanie Okey - $365K in CRNX purchases and sales in the last 12 months
- Coelho Rogerio Vivaldi - $301K in CRNX purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Matthew K. Fust?
Matthew K. Fust is a corporate insider, tracked as Director of Crinetics Pharmaceuticals, Inc. (CRNX). InsiderAlpha holds 7 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Matthew K. Fust submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has Matthew K. Fust been buying or selling stock?
Recorded transactions: 0 open-market purchases and 3 open-market sales ($1.09M) across all tracked filings.
